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ABSTRACT 
Tight protein-protein interactions (KRdR < 100 nM) that occur over a large binding interface (> 1,000 
ÅP2P) are highly challenging to disrupt with small molecules.  Historically, the design of small
molecules to inhibit protein-protein interactions has focused on mimicking the position of interface 
protein ligand side chains.  Here, we explore mimicry of the pairwise intermolecular interactions 
of the native protein ligand with residues of the protein receptor to enrich commercial libraries for 
small-molecule inhibitors of tight protein-protein interactions.  We use the high-affinity interaction 
(KRdR = 1 nM) between the urokinase receptor (uPAR) and its ligand urokinase (uPA) to test our 
methods. We introduce three methods for rank-ordering small molecules docked to uPAR: (i) a 
new fingerprint approach that represents uPA’s pairwise interaction energies with uPAR residues; 
(ii) a pharmacophore approach to identify small molecules that mimic the position of uPA interface 
residues; and (iii) a combined fingerprint and pharmacophore approach.  Our work led to small 
molecules with novel chemotypes that inhibited a tight uPAR•uPA protein-protein interaction with 
single-digit micromolar ICR50Rs. We also report the extensive work that identified several of the hits
as either lacking stability, thiol reactive, or redox active.  This work suggests that mimicking the 
binding profile of the native ligand and the position of interface residues can be an effective 
strategy to enrich commercial libraries for small-molecule inhibitors of tight protein-protein 
interactions. 
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INTRODUCTION 
 Protein-protein interactions range from weak (KRdR > 1000 nM), moderate (100 nM < KRdR < 
1000 nM), to tight (KRdR < 100 nM). P[1-3]P They are often classified as primary, secondary, or tertiary.[4] 
Primary interfaces are generally simple, involving a short linear peptide bound to the surface of 
another protein. Secondary interactions consist of an α-helix or β-turn that binds to a well-defined 
cavity of the receptor. Tertiary interactions are more complex, featuring large binding interfaces 
that often involve several secondary structures such as α-helices and β-strands.  Kastritis and co-
workers found that 68% of a set of 144 curated co-crystallized protein-protein interactions were 
both tight and occurred over a large binding interface (> 1000 Å2).[5]  Yet, despite the gradual 
increase in the number of  small-molecule protein-protein interaction inhibitors,[6-13] only a handful 
among them are inhibitors of tight protein-protein interactions.  Small-molecule inhibitors of tight 
interactions tend to be much larger than typical drugs, and generally have poor ligand binding 
efficiencies, which could explain the tendency for these compounds to fail in clinical trials.  The 
development of small molecules that disrupt tight protein-protein interactions could expand the 
number of druggable proteins for the development of therapeutic agents. 
Considering the ever-expanding size of commercial compound libraries, virtual screening 
could provide an avenue for developing chemical starting points that can be turned into potent 
inhibitors of tight protein-protein interactions.  To the best of our knowledge, one study has used 
virtual screening to identify small-molecule inhibitors of a tight protein-protein interaction without 
extensive cycles of design and synthesis.[14]  The most common approach for discovery of protein-
protein inhibitors involves the identification of a weak-affinity fragment whose affinity is optimized 
by growing the fragment into neighboring pockets. For Bcl-xL•Bax[10] and IL-2•IL2-Rα,[15] 
fragment-based approaches and synthesis of derivatives to optimize binding to pockets at the 
protein-protein interfaces led to highly potent small-molecule inhibitors of the protein-protein 
interactions. Recently, virtual screening of fragment libraries led to hit compounds and were 
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optimized into potent inhibitors of KEAP1•NRF2.[6]  In the case of uPAR•uPA, we used 
computational screening of commercial databases that led to IPR-803, which binds to uPAR with 
sub-micromolar binding affinity and disrupts the protein-protein interaction with single-digit 
micromolar ICR50Rs.[16, 17] The compound was discovered by virtual screening against a set of uPAR 
structures sampled from molecular dynamics simulations. Computational studies that include 
molecular dynamics simulations predicted a binding mode for the compound along with a critical 
salt-bridge interaction with an Arg-53[18] residue. Our predicted binding mode and interaction with 
Arg-53 was recently independently confirmed by a crystal structure of an analog of IPR-803 bound 
to uPAR.[19] 
Historically, most rational approaches for the design of small-molecule inhibitors of 
protein-protein interactions have focused on mimicking the position of amino acids located on the 
protein ligand of a protein-protein interaction.[20-22]  Several studies have used interface residues 
of the protein ligand of a protein-protein interaction to guide the design of small-molecule inhibitors 
in virtual screening and lead optimization.[23-29] The most common approach is based on 
pharmacophore modeling to enrich libraries for compounds that possessed substituents that not 
only adopted the same position as the amino acid side chain, but also possessed similar 
physicochemical properties to the side chain.  This strategy has worked reasonably well, although 
it is worth mentioning that there are no examples to date of small molecules that disrupt tight 
protein-protein interactions that emerged directly from virtual screening.  Another strategy 
consists of finding molecules that bind directly to the receptor with the hope that these compounds 
will disrupt the protein-protein interaction.  This strategy has never led to inhibitors of tight protein-
protein interactions.  This is attributed to the fact that mere binding to the receptor is not sufficient 
and critical residues, sometimes referred to as hot spots, must be engaged.  
Here, we explore a new approach that is focused on mimicking the pairwise binding profile 
of the native protein ligand to the protein receptor of a tight protein-protein interaction.  We use a 
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fingerprint approach to represent the binding profile of the protein ligand.  We use this fingerprint 
to screen commercial chemical libraries for small molecules that mimic the pairwise interaction 
profile of the native protein ligand.  We also consider the strategy of combining the fingerprint 
approach to the standard pharmacophore method that identifies molecules that mimic the position 
of protein ligand amino acids.  We use the tight uPAR•uPA protein-protein interaction as a 
platform to test these methods. We dock a library of commercially-available compounds to uPAR 
and rank compounds using the binding profile of the native ligand following three different 
methods. Compounds are tested for activity using fluorescence polarization and microtiter-based 
ELISA confirm disruption of the uPAR•uPA interaction. We also test for direct binding with 
microscale thermophoresis. All active hits are tested for thiol reactivity, redox activity, and stability. 
An analog-by-catalog procedure to explore structure-activity relationships led to the selection and 
testing of several derivatives for each hit compound.  To the best of our knowledge, this is the first 
example of the use of structure-based virtual screening that leads to small-molecule inhibitors of 
a tight protein-protein interaction. 
RESULTS 
uPAR•uPA as a Platform to Test Rank-Ordering Methods. The uPAR•uPA interface 
consists primarily of a β-turn on the protein ligand uPA ensconced in a large pocket on the protein 
receptor uPAR, leading to an interaction that is both tight (KRdR = 1 nM) and stable (kRoffR = 10-4 s-1) 
(Fig. 1 and Fig. S1a). Critical residues exist on both uPAR and uPA. In a comprehensive alanine 
scanning study, 15 residues on uPAR resulted in a significant decrease in binding affinity (∆∆G ≥ 
1 kcal mol-1) (Fig. S1b and Table S1).[30] Many of these residues, including Leu-55, Tyr-57, Leu-
66, and Leu-150, are located within the binding pocket of uPAR. Recently, using molecular 
dynamics (MD) simulations followed by free energy calculations, we found residues on uPAR that 
are engaged in strong van der Waals and electrostatic interactions with uPA, but do not result in 
a significant decrease in binding affinity; these include Arg-53 and Thr-127 (Fig. S1c and Table 
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S2).[17] On uPA, the side chain of five residues extend into the hydrophobic pocket of uPAR: Lys-
23, Tyr-24, Phe-25, Ile-28, and Trp-30 (Fig. S1a).[31] 
A New Fingerprint Method to Rank-Order Compounds Based on their Ability to 
Mimic the Binding Profile of uPA to Residues on uPAR. Although previous studies have used 
key residues on the protein ligand to guide the design of small-molecule inhibitors, interactions 
with residues on the receptor have been generally ignored.  Here, we utilize the interaction 
energies in the native protein-protein interaction to select top candidates that emerge from virtual 
screening of chemical libraries.  We introduce a new approach that uses the native ligand to 
identify compounds that mimic the protein ligand’s interaction with key receptor interface residues.  
To accomplish this, we use a fingerprint method summarized in Fig. 1. These fingerprints consist 
of strings of bits with length equal to the number of residues on the protein target, in our case 
uPAR. Each bit in the fingerprint corresponds to the interaction energy between the compound 
and a residue on uPAR.  If the interaction energy between the ligand and the residue is greater 
than a threshold, the value of the bit is assigned to ‘1’. For compounds, the interaction energy 
consists of the computational decomposition energy. A value of ‘1’ is assigned to a bit if the total 
decomposition energy (∆ER esidueR) is less than -1.0 kcal mol-1. For the native protein ligand, uPA, 
we generate two types of fingerprints based on either experimental data or computational 
decomposition energy. The first type of fingerprint is constructed using the experimentally-
determined alanine scanning data of the uPAR•uPA complex (Fig. S1b and Table S1). In this 
fingerprint, a value of ‘1’ is assigned to a bit if the change in free energy following mutation of the 
residue to alanine (∆∆GRAlaScanR) is greater than 1.0 kcal mol-1. The second fingerprint is constructed 
using the decomposition energies from the molecular dynamics simulation of the uPAR•uPA 
complex (Fig. S1c and Table S2). A value of ‘1’ is assigned to a bit if the total decomposition 
energy (∆ER esidueR) is less than -1.0 kcal mol-1. If the threshold is not met, the value of the bit is ‘0’. 
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Following the docking of small molecules from commercial libraries to uPAR, a fingerprint 
is generated for each protein-compound structure.  Each of these compound fingerprints is 
compared to the native protein ligand uPA fingerprint.  Compounds with the most similar 
fingerprints to the protein ligand uPA are given higher priority.  We use the Tanimoto distance 
(TRdR) to compare the similarity between compounds and protein ligand uPA fingerprint (Fig. 1). TRdR 
is defined as the ratio between the number of bits in the fingerprint where both uPA and the 
compound have a value of ‘1’ over the number of ‘1’ bits in the uPA fingerprint. The fingerprint 
generated from either alanine scanning or energy decomposition only includes positions where 
the corresponding uPA fingerprint has a value of ‘1’. However, the Tanimoto distance does not 
consider the positions of the specific bits when used to rank-order compounds. Similarly, the 
limited length of each fingerprint results in compounds sharing similar Tanimoto distances. If the 
Tanimoto distance of two compounds is equal, the total enthalpy from the MM-GBSA calculation 
of the compound (∆ERGBTOTR) is used to give higher priority to the compound with higher predicted 
binding affinity. 
Application of the Fingerprint Method to Rank-Order Compounds using uPAR 
Interface Residues. We use the uPAR•uPA interaction as a platform to test our fingerprint 
method to rank-order compounds based on their interaction with receptor interface residues.  The 
positions of the residues at the uPAR•uPA interface that were used to generate fingerprints are 
shown in Fig. 2a. Four residues on uPAR are present in both the uPA fingerprints based on the 
experimental alanine scanning and the fingerprints from energy decomposition: Leu-55, Leu-66, 
Leu-150, and His-166. 
We separately rank-order the 5.1 million docked compounds based on their TRdR value using 
(i) the uPA alanine scanning fingerprint and (ii) the uPA decomposition energy fingerprint. We 
select the top 500 candidates from each type of fingerprint. We examined how these compounds 
bind to each of these residues on uPAR (Fig. 2b). For compounds identified using the uPA 
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fingerprint derived from energy decomposition, over 90% of the selected compounds interact 
favorably with Arg-53, Leu-55, Leu-66, Leu-150, and Ala-255. His-166 and Asp-25 interact with 
41% and 86% of the compounds, respectively. For compounds identified using the uPA fingerprint 
derived from the experimental alanine scanning experimental data, 95% of the selected 
compounds interact with Leu-55, Leu-66, Leu-150, and His-166. Only 36% interacted with Arg-
53, a residue that was included in the decomposition but not the alanine scanning fingerprint. 
The top 500 compounds from both the energy decomposition and alanine scanning search 
strategies were independently clustered to 50 compounds using hierarchical clustering. Among 
the 50 compounds from each strategy, 29 from the uPA alanine scanning fingerprint and 24 from 
the uPA decomposition energy fingerprint were purchased for experimental validation. The 
fingerprints and MM-GBSA scores of the 29 and 24 compounds from the alanine scanning and 
decomposition energy fingerprints are listed in Table S3 and Table S4, respectively. These 53 
compounds were initially tested for binding to uPAR using a fluorescence polarization (FP) assay 
that we have previously developed (Fig. 2c).[16]  The assay consists of a fluorescently labeled α-
helical peptide (AE147-FAM) that binds to uPAR at the uPAR•uPA interface.  One compound, 1 
(IPR-2797), inhibited by more than 40%. A concentration-dependent study led to a KRiR of 7.1 ± 1.2 
µM (Fig. 2d). A follow-up study using a microtiter ELISA method to analyze the compound 
inhibition of the uPAR•uPARATFR interaction was performed. The compound did not show activity in 
the ELISA even at 100 µM. We next assessed 1 for both reactivity and stability. The potential for 
1 to covalently react with cysteine residues of a protein was evaluated using a (E)-2-(4-
mercaptostyryl)-1,3,3-trimethyl-3H-indol-1-ium (MSTI)-based assay.[32] The compound did not 
react with MSTI suggesting that it is not thiol reactive (Fig. S2). The compound was tested for 
redox activity by a Horseradish Peroxidase-Phenol Red (HRP-PR) assay and was found to be 
redox inactive at 100 µM concentration (Fig. S3). Compound stability was tested in methanol, 
phosphate-buffered saline (PBS), and in the presence of uPAR by high-performance liquid 
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chromatography-mass spectrometry (HPLC-MS). The compound showed the same retention time 
in HPLC and the mass remained the same, indicating that the compound is stable (Fig. S4). 
The predicted binding mode of 1 shows that the benzene of the benzofuran moiety 
overlaps with Phe-25 on uPA (Fig. 3a). In addition, a nitrogen in the piperazine ring of the 
compound is located near the positively charged amine on the side chain of Lys-23. Starting with 
the structure of 1, we searched commercially-available libraries for analogs to conduct a 
preliminary structure-activity relationship (SAR) study.  A set of 36 derivatives of 1 were identified, 
purchased, and screened at 50 µM using our FP assay (Fig. 3b). Three compounds, 2 (IPR-2944), 
3 (IPR-2962), and 4 (IPR-2966), showed 75%, 66%, and 82% inhibition, respectively (Fig. 3c). 
The compounds inhibited the uPAR•AE147-FAM interaction in a concentration-dependent 
manner (Fig. S5), although all were weaker than the parent compound. The most potent 
derivative, 4 (KRiR = 8.6 ± 1.1 µM), contains a fluorine atom on the aromatic ring of its benzofuran 
moiety.  
Selecting Rank-Ordered Compounds using uPA Interface Residues. We explore 
another ranking method that strictly uses the interface residues located on the ligand protein to 
guide the selection of compounds.  Our hypothesis is that small molecules docked to uPAR that 
mimic the side chain position of interface residues on the protein ligand will disrupt the uPAR•uPA 
interaction.  At the uPAR•uPA interface, the side chain of five interface residues on uPA extend 
into the hydrophobic pocket of uPAR: Lys-23, Tyr-24, Phe-25, Ile-28, and Trp-30 (Fig. 4a). We 
use a pharmacophore approach[33, 34] to identify compounds with substituents that occupy the 
same position as the side chains of these residues. This approach consists of searching for small 
molecules that possess substituents that overlap with similar moieties (pharmacophores) on the 
side chain of amino acids.  For example, a compound that possesses a benzene group that 
occupies the same position as the aromatic ring (pharmacophore) of a tyrosine residue is 
expected to disrupt binding of the residue to uPAR.  The features of the pharmacophore model 
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are shown in Fig. 4a. In the pharmacophore model, the ε-amine on Lys-23 was modeled using a 
positive charge, while the benzene rings of Tyr-24 and Phe-25 were modeled using aromatic 
rings. We assigned separate aromatic ring features to the benzene and pyrrole rings on the indole 
of Trp-30.  
For each of the 5.1 million docked compounds to uPAR, we determined whether there 
was an overlap with the defined pharmacophores on uPA. This resulted in 21312, 809846, 
1297014, and 23047 matches for Lys-23, Tyr-24, Phe-25, and Trp-30, respectively. We identified 
1899 compounds that overlapped with 3 of these 4 residues, and no compounds that overlapped 
with all four residues. These compounds were hierarchically clustered to 200 using atom triplet 
Daylight fingerprints. We identified 130 commercially-available compounds that were purchased. 
These compounds were tested for binding to uPAR using our FP assay (Fig. 4b). In total, 
approximately 1.8 million of the 5.1 million docked compounds overlapped with at least one of the 
pharmacophores corresponding to an interface residue on uPA (Fig. 4c). Among compounds that 
overlapped with a single residue, 54% and 27% matched the pharmacophores of Phe-25 and Tyr-
24, respectively. Less than 2% of compounds overlapped with either the Lys-23 or Trp-30 
pharmacophore. In contrast, 16% of compounds overlapped with both the Tyr-24 and Phe-25 
pharmacophores. 
We initially tested the 130 compounds for activity using our FP assay at 50 µM. We 
selected six compounds (5-10) that inhibited more than 40% (Fig. 4b). Compounds 5 (IPR-2477), 
6 (IPR-2496), and 9 (IPR-2532) overlapped with Tyr-24, Phe-25, and Trp-30, while 7 (IPR-2500), 
8 (IPR-2529), and 10 (IPR-2565) overlapped with Lys-23, Tyr-24, and Phe-25 (Fig. 4d). A 
concentration-dependent study for these compounds led to KRiR values that ranged from 6 to 97 µM 
(Fig. S6a). A follow-up study using a microtiter ELISA to analyze the compound inhibition of the 
uPAR•uPARATFR interaction was performed (Fig. S6b).  Although the ELISA cannot be used to obtain 
inhibition constants, it is a useful assay to determine whether compounds bind and disrupt the 
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protein-protein interaction between uPA and uPAR.  Four compounds, namely 6, 7, 9, and 10 
showed activity in the ELISA assay with ICR50Rs ranging from 7 to 230 µM.  
We assessed the reactivity and stability of all hit compounds. Compound 6 contains a Betti 
base that may cause the compound to be unstable and reactive, while 10 was thought to have a 
potential activated thiol group. The MSTI thiol reactivity assay was performed for each of the hits 
(Fig. S2). Compound 10 readily reacted with MSTI as evidenced by a decrease in the 
fluorescence of MSTI.  Compound 6 displayed no detectable MSTI reactivity, but we suspected 
that this was due to the unstable nature of the compound. The HRP-PR redox activity assay 
showed no significant redox capacity for compounds 5-10 (Fig. S3). At this point, we decided to 
pursue compounds 5, 6, 8, and 9. HPLC-MS stability assay for 8 and 9 showed the same single 
peak for both methanol and PBS buffers, indicating that the compounds were stable (Fig. S4). 
A set of 55 derivatives of 5 were purchased and screened using the FP assay at 50 µM. 
A number of compounds displayed significant inhibition (Fig. S7a). Three compounds (Fig. S7b), 
11 (IPR-2603), 12 (IPR-2605), and 13 (IPR-2606), were chosen to be further studied at several 
concentrations using FP (Fig. S7c) and ELISA (Fig. S7d). Compound 11 displayed better KRiR than 
the parent in the FP assay while all three compounds showed activity in the ELISA. MSTI assay 
of these three derivatives detected no thiol reactivity (Fig. S7e), but the reaction might be masked 
by assay interference, as all three compounds are yellow when dissolved in the assay buffer. The 
compounds showed no appreciable redox activity (Fig. S3). However, the HPLC-MS study 
revealed that all the compounds were mixtures as shown for 12 (Fig. S4). This suggests that the 
compound series may be unstable and inhibits through a non-specific mechanism. This is further 
supported by the fact that despite the differences in structure between 11, 12, and 13, the three 
compounds exhibit similar KRiRs in the FP assay and ICR50R in the ELISA. 
Compound 6 was pursued with reservation considering the reactive Betti base. 
Compounds 14-17 were purchased, and we synthesized 18 (IPR-2804) that lacked the hydroxyl 
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group of the Betti base (Fig. S8a). Compounds were initially tested at 50 µM and then in a 
concentration-dependent manner using the FP assay and ELISA (Fig. S8b). The compounds with 
the Betti base moiety inhibited substantially, while 18 showed no activity in either assay. The 
complete lack of activity of 18, despite its structural similarity with the parent compound, strongly 
suggested that the activity of 6 and derivatives was non-specific.  This is further confirmed by the 
MSTI assay, which shows 18 to be non-reactive while 14-17 are reactive (Fig. S8c). Compound 
17 (IPR-2665) did not bind to uPAR using microscale thermophoresis (data not shown). To 
determine whether the compounds reacted with uPARATFR as well as uPAR, the ELISA setup was 
slightly modified, whereby we pre-incubated immobilized uPARATFR with the compounds for 30 min, 
followed by the washing step, which discarded all compounds in the well, followed by addition of 
uPAR. Despite the complete lack of contact of the compound with uPAR, both compounds 6 and 
17 displayed significant inhibition at 50 µM concentration, while our reversible uPAR inhibitor, 
IPR-1109,[35] was washed away and did not inhibit (Fig. S8d). This suggested that the compounds 
were also forming adducts with uPA further supporting a non-specific mechanism.  To test for 
specificity, 17 was tested in two other FP assays against TEAD4 transcription factor and voltage-
gated calcium channel β-subunit 3 (CaRVRβR3R) proteins; they inhibited in both assays (Fig. S8e). 
Compounds 6 and 17 showed no redox activity on the HRP-PR assay (Fig. S3). HPLC-MS 
analysis of 6 showed that the compound broke down in methanol and PBS buffer, resulting in 
weak UV signals. This confirmed that the compounds were unstable.  The total ion count 
chromatogram showed three distinct peaks, the intact 6 and two fragments (Fig. S8f).  This 
compound series was not pursued further. 
Compound 8 binds to uPAR with double-digit micromolar affinity (KRiR = 37.2 ± 19.8 µM) 
based on the FP assay. The binding mode from the virtual screen shows that the compound’s 
morpholino, methylphenyl, and methoxyphenyl groups overlap with Lys-23, Tyr-24, and Phe-25, 
respectively (Fig. 5a). A search of the ZINC chemical library identified 37 derivatives that were 
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purchased and screened at 50 µM using our FP assay (Fig. 5b). Two derivatives, 19 (IPR-2916) 
and 20 (IPR-2922) (Fig. 5c) were chosen and tested by concentration-dependent FP (Fig. S9a) 
and ELISA (Fig. S9b). The compounds showed weak KRiR and ICR50R values, but they provide a 
starting point for the development of more potent inhibitors of the very tight protein-protein 
interaction. 
Compound 9 binds to uPAR with affinity near 100 µM (FP KRiR = 97.4 ± 61.2 µM, ELISA ICR50R 
= 230.6 ± 41.7 µM). The virtual screening binding mode of 9 is shown in Fig. 5d.  On one end of 
the compound, the dimethoxybenzene overlaps with Trp-30. On the other end, the acyl 
morpholine is buried into the binding pocket. A benzene ring near this moiety overlaps with Phe-
25, while a pyrimidine in the core overlaps with Tyr-24. A total of 8 derivatives were purchased 
and screened by the single-concentration FP assay (Fig. 5e). None of the derivatives showed 
strong similarity to the parent compound.  As a result, most of these derivatives showed even 
weaker binding and inhibition than 9.  The best compounds were 21 (IPR-2940) and 22 (IPR-
2942) (Fig. 5f), which we tested by concentration-dependent FP (Fig. S10a) and ELISA (Fig. 
S10b).  
Selecting Rank-Ordered Compounds using both uPA and uPAR Interface Residues. 
We wondered whether combining our fingerprint method with the pharmacophore approach could 
yield small-molecule uPAR•uPA inhibitors. We combined the two search methods to identify a set 
of 69 compounds that overlapped with three of the four interface residues on uPA as well as 
engage residues in the uPA binding pocket on uPAR. A set of 39 compounds selected from 
among the 69 compounds were purchased for binding studies. The fingerprints and MM-GBSA 
scores of the 15 and 24 compounds from the alanine scanning and decomposition energy 
fingerprints are listed in Table S5 and Table S6, respectively. The 39 compounds were tested in 
our FP assay (Fig. 6a). Seven compounds (23-29) were assessed using a concentration-
dependent manner to determine the KRiR values (Fig. 6b and S11a). Compounds 23 (IPR-2986), 26 
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(IPR-2992), 27 (IPR-2993), 28 (IPR-3089), and 29 (IPR-3193) overlapped with Lys-23, Tyr-24, 
and Phe-25 on uPA, while 24 (IPR-2987) and 25 (IPR-2989) overlapped with Tyr-24, Phe-25, and 
Trp-30. In comparison to hits that emerged from fingerprint or pharmacophore methods, the 
compounds had better KRiR values that ranged from 6 to 52 µM. Only 25, 26, 28, and 29 inhibited 
uPAR•uPARATFR based on a concentration-dependent study using our ELISA (Fig. S11b).  The 
compounds had ICR50R values of 68.3 ± 11.0, 140.6 ± 19.0, 172.8 ± 42.5, and 24.8 ± 2.2 µM in the 
ELISA, respectively. The presence of α,β-unsaturated carbonyls on 23, 24 and 27 suggested 
potential reactivity with residue on uPAR and uPA.  However, none of the hits from this screen 
showed reactivity with the activated thiol of the MSTI compound suggesting that the activity of the 
compounds is unlikely due to covalent bond formation (Fig. S2). Compounds 24 and 27 displayed 
slight redox capacity in the HRP-PR assay, while compounds 23, 25, 26, 28, and 29 showed no 
redox activity (Fig. S3). We focused our attention on 26, 28, and 29 as these compounds do not 
contain any problematic moiety and showed no covalent reaction or redox activity.  HPLC-MS 
analysis of these three compounds (Fig. S4) showed the compounds to be stable in both methanol 
and PBS buffers, with similar retention times. 
Compound 26 binds into the uPAR•uPA pocket, mimicking the side chains of uPA and 
engaging interface residues on uPAR (Fig. 7a). A benzene moiety overlaps with Phe-25 on uPA. 
In the binding mode, a morpholino group is located between Lys-23 and Tyr-24 of uPA. In addition, 
a methyl substituent on the core quinoline ring points towards Trp-30. The core structure of 26 
was used to identify derivatives. The derivatives we identified showed modifications at five 
substituents on 26 (Fig. 7b). A set of 136 derivatives of 26 were purchased and screened at 50 
µM (Fig. 7c). The best hits were tested in concentration-dependent manner and their KRiRs ranged 
from 2 to 37 µM (Table 1 and Fig. S12a). The compounds were further tested in the uPAR•uPARATFR 
ELISA assay to determine whether they can inhibit the protein-protein interaction (Table 1 and 
Fig. S12b). Only 32 (IPR-3026) and 39 (IPR-3116) failed to inhibit in the ELISA. The best 
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derivative among the 26 derivatives was 30 (IPR-3011). The binding mode of 30 shows that the 
additional moiety fits into a pocket lined by Asn-157, His-166, Leu-168, and Ala-255 on uPAR 
(Fig. 7a). The FP and ELISA inhibition curves of 26 and 30 are shown in Fig. 7d and Fig. 7e, 
respectively. The KRiR and ICR50R in the FP and ELISA assays for 30 are 2.5 ± 0.3 and 15.5 ± 1.4 µM, 
respectively. Compounds 26 (Fig. 7f) and 30 (Fig. 7g) were tested using microscale 
thermophoresis to assess direct binding to uPAR. The resulting KRdR of 26 and 30 towards uPAR 
were 5.8 ± 1.3 and 2.0 ± 0.4 µM, respectively, consistent with the FP data for these compounds. 
Compound 30 and several of the other 26 derivatives have limited solubility. Like its parent 26, 
30 displayed no significant redox activity at 100 µM (Fig. S3). 
The binding mode of 28 shows overlap with Lys-23, Tyr-24, and Phe-25 on uPA (Fig. 8a). 
A set of 59 derivatives of 28 were purchased and screened by single concentration FP at 50 µM 
(Fig. 8b). The six best compounds, 44-49 (Fig. 8c), were tested in a concentration-dependent 
manner using the FP assay (Fig. S13). While the analogs had KRiR values ranging from 5 to 160 
µM, the compounds did not inhibit in the ELISA. The first set of analogs, 44-46, modify both the 
biphenyl and methyl group on the benzimidazole of the parent compound, yielding compounds 
that were less potent than the parent compound. The second set of analogs, 47-49, modifies only 
the methyl group on the benzimidazole. Compound 49 (IPR-3485) lacks the methyl group entirely, 
resulting in threefold weaker inhibition constant than the parent. Compounds 47 and 48 possess 
aromatic substituents instead of the methyl group, resulting in KRiRs of 5 µM in the FP assay. The 
lack of inhibition in the ELISA suggests that the compounds, while robust, may not be engaging 
the right set of residues to disrupt the full protein-protein interaction. 
The binding mode of 29 reveals overlap with Lys-23, Tyr-24, and Phe-25 on uPA (Fig. 8d). 
A set of 20 derivatives of 29 were purchased and screened at 50 µM (Fig. 8e). The five best 
compounds, 50-54 (Fig. 8f), were tested at multiple concentrations using FP (Fig. S14a) and 
uPAR•uPARATF RELISA (Fig. S14b). All but 53 (IPR-3235) (FP KRiR = 5.6 ± 0.6 µM, ELISA ICR50R = 52.0 
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± 4.1 µM) and 54 (IPR-3236) (FP showed no inhibition; ELISA ICR50R = 65.3 ± 12.3 µM) had limited 
solubility in the two assays. Compound 29 was tested for direct binding in the MST assay and 
binds to uPAR with a KRdR of 22.7 ± 11.5 µM (Fig. S14c). 
DISCUSSION 
The design of small-molecule inhibitors of protein-protein interactions has primarily 
focused on developing small molecules that bear substituents that mimic the position of amino 
acid side chains of the protein ligand in a protein-protein interaction.  Here, we complement this 
approach by exploring a strategy that searches for small molecules that mimic the binding profile 
of the native protein ligand to the receptor of a protein-protein interaction.  We hypothesize that 
small molecules that mimic the interaction of the native protein ligand to receptor are more likely 
to disrupt tight protein-protein interactions.  To test this hypothesis, we introduced a quantitative 
approach to enable the comparison of the binding profiles of compounds to the binding profile of 
the protein ligand.  We use a bitwise fingerprint to represent the pairwise interactions with amino 
acids on the receptor.  When the ligand (protein or compound) engages a residue above a 
threshold, we assign the bit as ‘1’.  The pairwise binding is based on the decomposition energy 
method that was introduced by Gohlke and co-workers to study the effect of individual amino 
acids on a protein-protein interaction.[36]  The decomposition energy consists of the intermolecular 
energy between the ligand and each amino acid.  This energy includes van der Waals, 
electrostatic, and polar and non-polar solvation energies.  Following the creation of a fingerprint 
for the native protein ligand, in our case uPA, we used structure-based virtual screening to identify 
small molecules that shared a similar fingerprint.  To do this, we docked a large number of 
compounds to uPAR, and generated fingerprints for all these compounds using the predicted 
binding pose.  Compounds were ranked based on how closely their fingerprint matched the native 
ligand’s (e.g. uPA).  To accomplish this, we borrow from the cheminformatics field and use the 
Tanimoto distance to quantify the similarity between fingerprints.  The top candidates that 
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emerged from this screen were purchased and tested for binding to uPAR.  Among them, we 
found one hit, 1 (IPR-2797), that inhibited a fluorescently-labeled peptide with an inhibition 
constant KRiR of 7 µM.  Analogs of 1 were purchased, confirming the activity of the parent compound 
and providing an opportunity for structure-activity relationships.  Neither 1 nor its derivatives 
inhibited in our ELISA, which includes the entire protein-protein interaction interface.  This 
suggests that improvements could be made to this method, such as perhaps focusing only on the 
most critical residues on the receptor.  A more stringent threshold for picking interface amino 
acids could make this possible.  Another possibility is that there exists a combination of residues 
that must be engaged to disrupt a protein-protein interaction, and that compound 1 does not 
engage the right combination of residues.  Regardless, the compound offers an excellent starting 
point to develop potent small-molecule inhibitors of the tight uPAR•uPA protein-protein 
interaction.  We found the compound to have good solubility, does not react with uPAR, and is 
not redox active.  It is also stable in methanol and buffer as evidenced by LC-MS analysis. 
Another strategy that we followed was driven by the hypothesis that small molecules that 
possess substituents that mimic the position of protein ligand amino acid side chains will more 
likely disrupt the protein-protein interaction. This is a widely used method, but to the best of our 
knowledge has never been applied for the discovery of small-molecule inhibitors of tight protein-
protein interactions.  We resorted to pharmacophore modeling to score compounds based on how 
effectively they overlap with native protein ligand residue side chains of uPA.  This approach 
resulted in more hit compounds than the screen using receptor amino acids alone.  However, 
close inspection of the structure of these compounds revealed potentially problematic groups, 
such as a Betti base in compound 6 (IPR-2496) that could result in unstable compounds, or a 
thiol reactive moiety in compound 10 (IPR-2565) that may lead to adduct formation with 
nucleophilic residues on uPAR.  Among all the compounds, we confirmed that 10 is thiol reactive.  
Compound 6 was unstable, as expected, despite the single-digit inhibition in both the FP and 
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ELISA assays for a series of derivatives.  In fact, we confirmed that the activity of the compound 
was due to non-specific reactivity through the synthesis of 18 (IPR-2804), a derivative that lacked 
the Betti base. Despite the lack of obvious unstable or reactive moieties for compound 5 (IPR-
2477), we found it to be unstable and its activity is likely due to assay interference or reactivity 
with assay or protein.  Compounds 8 (IPR-2529) and 9 (IPR-2532) were the most robust 
compounds we identified.  Only compound 9 inhibited in both the FP and ELISA suggesting that 
it could be a good starting point for the development of uPAR•uPA inhibitors.  Its large size, 
however, may make it difficult to optimize.  Compound 8 did not inhibit uPAR•uPA in our ELISA 
suggesting that the compound binds, but it may not effectively mimic uPA residues.  It is also 
possible that the compound binds to residues on uPAR that negate the benefits of mimicking uPA.  
Finally, we wondered whether the use of interface residues on both uPAR and uPA could 
lead to better inhibitors from virtual screening. We combined our fingerprint and pharmacophore 
methods to rank-order compounds docked to uPAR.  It is interesting that this method led to even 
more hit compounds than using fingerprint or pharmacophore alone.  A total of seven hits were 
identified.  Despite the initial concern that three of the compounds had potentially problematic α,β-
unsaturated carbonyls, such as in 23 (IPR-2986), 24 (IPR-2987), or 27 (IPR-2993), none of the 
compounds were found to be thiol reactive.  One compound had an acylhydrazine moiety that 
could also be unstable at low pH, although our work is done at pH 7 suggesting that the compound 
should be stable.  An interesting feature of these compounds compared to those that emerged 
from using strictly the pharmacophore method is that they had fewer rotatable bonds overall, and 
two compounds, namely 26 (IPR-2992) and 28 (IPR-3089) were fragment-like.  Compound 26 
was particularly interesting as it inhibited, albeit weakly, in both our FP and ELISA assays.  
Starting with 26, we followed an analog-by-catalog approach and purchased several derivatives.  
Among the derivatives, we discovered several compounds, including 30 (IPR-3011), which 
exhibited substantially higher binding affinity than the parent fragment-like compound.  We 
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confirmed direct binding of both 26 and 30 using microscale thermophoresis with KRdR values that 
were similar to the KRiRs values measured by FP.  30 also possessed substantially better ICR50Rs 
(single-digit micromolar range) in the disruption of the full uPAR•uPA interaction.  Future 
optimization will focus on improving solubility of these derivative compounds, and exploring 
additional substituents for 26.  The methyl group located on the quinoline ring points towards the 
side chain of a critical tryptophan on uPA.  The introduction of moieties that mimic the tryptophan 
side chain may result in substantially greater potency. 
In sum, we present a new approach to identify small-molecule inhibitors of tight protein-
protein interactions that uses the native ligand’s pairwise intermolecular interactions with the 
receptor of a protein-protein interaction. When combined with a pharmacophore approach that 
uses the native protein ligand interface amino acids, we identified robust small-molecule inhibitors 
of the tight uPAR•uPA. To the best of our knowledge, this is the first example of a virtual screen 
that uses the crystal structure of a tight protein-protein interaction and identified single-digit 
micromolar small-molecule inhibitors.  These results suggest that while commercial libraries do 
not cover chemical space that is typical of protein-protein interaction inhibitors, it is possible to 
identify robust starting points that could be used to develop small-molecule inhibitors of tight 
protein-protein interactions.  The results also show that virtual screening is also prone to nuisance 
compounds as several of the small molecules that initially showed promising activity were working 
through a non-specific mechanism.  Finally, it is worth mentioning that small-molecule inhibitors 
that emerged from this work are structurally distinct from inhibitors that we previously identified 
for uPAR.  We compared the structure of compounds 1-54 to our previously reported uPAR•uPA 
inhibitors IPR-803[16] and IPR-1110.[17, 35] The similarity between these compounds was assessed 
using atom triplet Daylight fingerprints. We find that generally, the Tanimoto similarity between 
compounds 1-54 and our previously described inhibitors range from 0.05 to 0.10. 
MATERIALS AND METHODS 
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Virtual Screening. A set of commercially-available compounds from ChemDiv Inc. (San 
Diego, CA), ChemBridge Corporation (San Diego, CA), Life Chemicals (Munich, Germany), 
Princeton BioMolecular Research Inc. (Princeton, NJ), Specs (Zoetermeer, Netherlands), and 
Vitas-M Laboratory Ltd (Hong Kong) were retrieved from ZINC.[37] Small molecules in this library 
possessing pan-assay interference compound (PAINS)[38] or rapid elimination of swill (REOS)[39] 
moieties were filtered out using the Canvas package in Schrödinger (Schrödinger LLC, New York, 
NY, 2015). This resulted in a compound library of approximately 5.1 million small molecules. 
Individual MOL2 formatted files were converted to PDBQT format using the prepare_ligand4.py 
script in MGLTools.[40]  
The structure of the uPAR•uPA complex (PDB ID: 3BT1) was retrieved and prepared using 
Protein Preparation Wizard in Schrödinger.[41] Bond orders were assigned, hydrogen atoms were 
added, and disulfide bonds were created. Vitronectin (chain B) was removed and the missing loop 
at residues Arg-83 and Ala-84 were introduced using the Prime module. The resulting structure 
was protonated at pH 7.0 using PROPKA[42] and separated into its respective monomeric chains. 
The uPAR structure (chain U) was converted to PDBQT format using the prepare_receptor4.py 
script in MGLTools. 
The compound library was docked to the prepared uPAR structure using AutoDock 
Vina.[40] The binding pocket was centered at the uPAR•uPA interface with a box with dimensions 
of 21 Å × 21 Å × 21 Å. All other parameters were set to default values. The docked conformations 
were converted back to MOL2 format using in-house Python scripts for additional analysis. 
 uPAR Interface Residues. To find compounds that overlapped with residues on uPAR in 
the uPAR•uPA complex, we resorted to a fingerprint approach that utilizes interaction energies 
between the receptor and ligand. The workflow of the fingerprint approach is described in Fig. 
S15. We determined the interaction energies of each docked compound to individual residues of 
uPAR using the Generalized Born Surface Area (GBSA) method in the Amber14 and 
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AmberTools15 software packages.[43] Each docked compound was assigned Gasteiger charges 
and gaff[44] atom types using the antechamber program.[45] Additional force field parameters were 
generated using the parmchk program. Topology and coordinate files for the docked complex and 
individual receptor and ligand were generated with ff14SB[46] and gaff[44] force fields using the 
tleap program. These topology and coordinate files were used as inputs to calculate the free 
energies and per-residue decomposition energies in the MMPBSA.py script.[47] The MMPBSA.py 
script was modified to include the missing atom radius for iodine atoms.[48] The calculation using 
the Generalized Born (GB) method was performed with sander and Onufriev’s GB model.[49, 50] 
Solvent-accessible surface area (SASA) calculations were switched to the icosahedron (ICOSA) 
method, where surface areas are computed by recursively approximating a sphere around an 
atom, starting from an icosahedron. Salt concentration was set to 0.1 M. Compounds with 
combined internal and solvation terms (∆ERGBTOTR) greater than -5.0 kcal mol-1 were discarded. 
For each docked compound, we generate a one-dimensional array with length equal to 
the total number of residues of the uPAR structure. In this vector, each position corresponds to 
an individual residue of uPAR. Each position is assigned a value of ‘1’ (ON) or ‘0’ (OFF) based 
on the residue decomposition energy at that position and acts as a fingerprint for that compound. 
If the energy at the given residue is less than -1.0 kcal mol-1, we assign the position a value of ‘1’. 
Otherwise, we assign the position a value of ‘0’. Residues for the fingerprints were identified from 
two sources: (i) an experimentally-determined alanine scanning of uPAR from Gårdsvoll and 
coworkers[30] (Table S1); and (ii) a previously described molecular dynamics (MD) simulation of 
the uPAR·uPA complex (Table S2).[17] Similar to the construction of the compound-specific bitwise 
arrays, we create vectors for each type of fingerprint where each position corresponds to an 
interaction energy of the uPAR•uPA complex. In the vector corresponding to the experimental 
alanine scan, a position was assigned a value of ‘1’ if the ∆∆G at that residue is greater than 1.0 
kcal mol-1 and ‘0’ otherwise. In the vector corresponding to the per-residue decomposition 
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energies, a position is assigned a value of ‘1’ if the total energy (∆ERGBTOTR) at that residue is less 
than -1.0 kcal mol-1 and ‘0’ otherwise. 
In both fingerprints, only a small portion of uPAR will have values of ‘1’ with its native 
ligand uPA. Therefore, we reduce the length of each fingerprint to only include positions with ‘1’ 
bits in the uPAR•uPA complex. For each docked compound, we calculate the Tanimoto distance 
between the fingerprints of the complex and the compound in a bitwise manner. The fingerprint 
of the uPAR•uPA complex consists of only ‘1’ bits. Thus, this distance can be simply calculated 
by summing the number of ‘1’ bits in the compound fingerprint and dividing by the length of the 
fingerprint. Compounds were rank-ordered based on their Tanimoto distance, and in cases where 
compounds had the same Tanimoto distance, we used ∆ERGBTOTR to rank these compounds. 
uPA Interface Residues. A pharmacophore-based approach was used to identify docked 
compounds that overlapped with and mimicked interface residues on uPA. We used four residues 
of uPA at the uPAR•uPA interface: Lys-23, Tyr-24, Phe-25, and Trp-30. For each residue, we 
defined a pharmacophore hypothesis corresponding to the physiochemical properties of the 
individual residue’s side chain using the Phase package in Schrödinger.[33, 34] Phase has six built-
in types of pharmacophore features: (i) hydrogen bond acceptor, (ii) hydrogen bond donor, (iii) 
hydrophobe, (iv) negative ionizable, (v) positive ionizable, and (vi) aromatic ring. We assigned a 
positive charged feature to the ε-amine on Lys-23 and aromatic rings features to the aromatic 
rings of Tyr-24, Phe-25, and Trp-30. A single pharmacophore feature was assigned to the 
benzene rings of Tyr-24 and Phe-25, while two separate pharmacophores were assigned to the 
pyrrole and benzene rings of the bicyclic indole on Trp-30. We searched for compounds 
containing ligand moieties that matched a corresponding pharmacophore feature. A compound 
that matched either of the two aromatic pharmacophore features on Trp-30 was considered to 
overlap and mimic the residue.  Each pharmacophore feature was screened independently of one 
another. The aromatic and positively charged pharmacophores are represented as spheres 
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centered on the side chain moiety with radii of 1.5 Å and 0.75 Å, respectively. Compound 
conformers from virtual screening were used to identify matches without refinement using Phase’s 
default fitness function. In this scoring function, three factors are used to describe the degree to 
which a compound matches a pharmacophore feature: (i) the site score, which describes how 
well the compound superimposes the pharmacophore feature, (ii) the vector score, which 
describes the cosine angle between the normal vector of an aromatic ring on the compound with 
an aromatic feature, and (iii) the volume score, which describes the proportion of the total volume 
of the pharmacophore feature overlapped by the compound. Compounds with either root-mean-
square deviation (RMSD) overlap greater than 1.2 Å or did not overlap with the pharmacophore 
feature were discarded. For the aromatic pharmacophores, no consideration was given to the 
angle between the normal vectors of an aromatic feature and the orientation of an aromatic ring. 
All other parameters were set at default values. The remaining compounds that matched a given 
pharmacophore was retained without sorting compounds by Phase’s internal scoring function. 
Compounds that matched 3 of the 4 residues were retained. 
Selection of Compounds. The top-ranking compounds following virtual screening using 
uPAR and uPA residues were retrieved and clustered using the Canvas package in Schrödinger. 
A hashed binary fingerprint corresponding to atom triplets of Daylight invariant atom types were 
generated for these top-ranking compounds. Compounds were then hierarchically clustered using 
their atom triplet fingerprints and average linkage clustering. The Tanimoto similarity between a 
pair of fingerprints was used as the distance metric. Compounds corresponding to the cluster 
centers from hierarchical clustering were purchased for experimental validation. 
Microtiter-Based ELISA for uPAR•uPA. uPAR without the glycosylphosphotidylinositol 
(GPI) anchor was obtained by a purification process as previously described.[51] High-binding 
microplates (Greiner Bio-One, Kremsmünster, Austria) were incubated for 2 h at 4 °C with 100 μL 
of 4 μg mL–1 of uPARATFR in PBS for immobilization as previously described.[16] The plate was 
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washed with 0.05% Tween-20 in PBS buffer between each step. A 1:1 mixture of Superblock 
buffer in PBS (Thermo Fisher Scientific, Inc. Waltham, MA) with 0.04 M NaHR2RPOR4R and 0.3 M NaCl 
buffer was used for blocking at room temperature for 45 min. Following removal of the blocking 
buffer and washing, 100 µL of 0.85 nM uPAR in PBS with 0.01% triton X-100 was added with 100 
to 0.4 μM compounds in 1% v/v DMSO. Following incubation for 30 min and subsequent washing 
steps, biotinylated human uPAR antibody (1:3000 dilution of 0.2 mg mL–1 BAF807, R&D Systems, 
Minneapolis, MN) in PBS containing 1% bovine serum albumin (BSA) was added to the wells 
(100 μL/well) and incubated for 1 h to allow for the detection of bound uPAR. Following washing, 
streptavidin-horseradish-peroxidase in PBS containing 1% BSA was added to the wells and 
incubated for 20 min. The signal developed in the presence of 3,3’,5,5’-tetramethylbenzidine 
(TMB) in phosphate-citrate buffer (pH 5) and hydrogen peroxide was stopped by adding HR2RSOR4R 
solution and was detected using a SpectraMax M5e (Molecular Devices, Sunnyvale, CA). When 
compounds were insoluble and visible precipitation was observed, the data points at the high 
concentrations were not included in the calculation of ICR50R values. 
Fluorescence Polarization (FP) Assay. Polarized fluorescence intensities were 
measured using EnVision Multilabel plate readers (PerkinElmer, Waltham, MA) with excitation 
and emission wavelengths of 485 and 535 nm, respectively.[16] Samples were prepared in Thermo 
Scientific Nunc 384-well black microplate in duplicates. First, the compounds were serially diluted 
in DMSO and further diluted in 1× PBS buffer with 0.01% Triton X-100 for a final concentration of 
200 – 0.2 μM. Triton X-100 was added to the buffer to avoid compound aggregation. 5 μL of the 
compound solution and 40 μL of PBS with 0.01% Triton X-100 containing uPAR was added to the 
wells and incubated for at least 15 min to allow the compound to bind to the protein. Finally, 5 μL 
of fluorescent AE147-FAM peptide solution was added for a total volume of 50 μL in each well 
resulting in final uPAR and peptide concentrations of 320 nM and 100 nM respectively. The final 
DMSO concentration was 2% v/v, which had no effect on the binding of the peptide. Controls 
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included wells containing only the peptide and wells containing both protein and peptide each in 
duplicates to ensure the validity of the assay. A unit of millipolarization (mP) was used for 
calculating percentage inhibition of the compounds. When compounds were insoluble and visible 
precipitation was observed, the data points at the high concentrations were not included in the 
calculation of ICR50R values. Inhibition constants were calculated from the ICR50R values using the KRiR 
calculator available at 33TUhttp://sw16.im.med.umich.edu/software/calc_ki/U33T.  
Microscale Thermophoresis (MST). uPAR was labeled with NT-495 fluorescent dye 
(Nanotemper, Munich, Germany) according to the manufacturer’s instructions. Compounds were 
serially diluted in DMSO and further diluted in PBS buffer with 0.025% v/v Tween-20. 10 µL of 
fluorescently-labeled uPAR and 10 µL of compound solution were combined to final 
concentrations of 40 nM fluorescently-labeled uPAR, 2% v/v DMSO and compound 
concentrations ranging from 200 µM to 0.1 µM. The protein-compound solution was incubated for 
10 min at room temperature in the dark, before being taken up in Monolith NT.115 series standard-
treated capillaries. The capillaries were measured on Monolith NT.115 (Nanotemper, Munich, 
Germany) at 25 ºC, with LED power at 40% and MST power at 40%, and the MST was measured 
for 30 s. The data was analyzed using the “Thermophoresis with T-jump” function within the 
NanoTemper Affinity Analysis version 2.0.2 software (Nanotemper, Munich, Germany). The data 
was then fit with the “KRdR Model” function within the software to calculate the KRdR. 
(E)-2-(4-mercaptostyryl)-1,3,3-trimethyl-3H-indol-1-ium (MSTI) Assay. MSTI assay 
was performed according to the manufacturer’s recommendations (Kerafast, Inc. Boston, MA).[32] 
A 10 mM solution of acetyl-MSTI was added to 50 mM PBS buffered solution at pH 12.0 with 50% 
v/v methanol in a ratio of 1:10 v/v. After mixing and incubating for 2 min at room temperature, the 
solution was diluted with 50 mM PBS at pH 7.4, containing 0.01% NP-40 and 5% v/v methanol to 
generate a final concentration of 30 µM MSTI at pH 7.4. 19.6 µL aliquots of the MSTI solution was 
dispensed in 384-well flat-bottom black plate and 0.4 µL of 5 mM compounds in DMSO were 
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added make a 100 µM final concentration. Unreacted MSTI solution without added compound, 
but with equal amount of DMSO, was used as a negative control, while unactivated acetyl-MSTI 
solution with DMSO was used as a positive control. The plate was then incubated with shaking 
for 30 min at room temperature and the fluorescence intensities were measured using a 
Flexstation 3 plate reader (Molecular Devices, Sunnyvale, CA) at excitation and emission 
wavelengths of 510 and 650 nm, respectively. 
Horseradish Peroxidase-Phenol Red (HRP-PR) Redox Activity Assay. HRP-PR assay 
was performed according to the published protocol.[52, 53] In brief, 20 µL of 300 µM compounds in 
3% v/v DMSO in Hank’s balanced salt solution (HBSS) (Cat. No. SH30268.02; HyClone, Logan, 
UT) was dispensed into a 384-well clear, flat-bottomed polystyrene plate (Cat. No. 781101; 
Greiner Bio-One, Monroe, NC). Controls with 3% v/v DMSO and 300 µM HR2ROR2R were dispensed. 
20 µL of 2.4 mM fresh dithiothreitol (DTT) in HBSS was added to each well. For the HR2ROR2R controls, 
20 µL HBSS with no DTT was added. After 5 min incubation at RT, 20 µL solution of 300 µg ml-1 
Phenol Red (Cat. No. P-2417; Sigma-Aldrich, St. Louis, MO), 180 µg ml-1 HRP (Cat. No. P-2088; 
Sigma-Aldrich, St. Louis, MO) was added. After 20 min incubation at room temperature, the 
absorbance was read at 610 nm on a SpectraMax M5e (Molecular Devices, Sunnyvale, CA). 
High-Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS). 
Compounds at 200 µM were incubated in methanol, PBS, or 30 µM uPAR in PBS for 1 h at room 
temperature. The samples were injected onto a Kinetex 2.6 µm XB-C18 100 Å column (Cat. No. 
00B-4496-E0; Phenomenox, Torrance, CA) on an Agilent 6130 Quadrupole LC/MS system 
(Agilent, Santa Clara, CA). Compounds 6 (IPR-2496), 12 (IPR-2605), and 29 (IPR-3193) were 
eluted by a linear gradient from Buffer A (HR2RO) to Buffer B (acetonitrile, 5 mM NHR4ROAc) over 15 
min. Compounds 1 (IPR-2797), 8 (IPR-2529), 9 (IPR-2532), 26 (IPR-2992), and 28 (IPR-3089) 
were eluted by a linear gradient from Buffer A (HR2RO, 0.1% formic acid) to Buffer B (acetonitrile, 
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0.1% formic acid) over 15 min. Column elution was tracked by UV absorption at 256 nm and the 
masses were detected by positive ion mode.  
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ABBREVIATIONS USED 
CaRVRβR3R  voltage-dependent L-type calcium channel subunit beta-3 
FP  fluorescence polarization 
GB  Generalized Born 
HRP-RP Horseradish Peroxidase-Phenol Red 
KRdR  disassociation constant 
MM-GBSA molecular mechanics generalized Born surface area approach 
MST  microscale thermophoresis 
MSTI  (E)-2-(4-mercaptostyryl)-1,3,3-trimethyl-3H-indol-1-ium 
PAINS  pan-assay interference compound 
PPI  protein-protein interaction 
REOS  rapid elimination of swill 
SAR  structure-activity relationship 
TEAD4 transcriptional enhancer factor TEF-3 
uPAR  urokinase plasminogen activator surface receptor 
uPA  urokinase-type plasminogen activator 
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Table 1. Profiles of Analogs of Compound 26 (IPR-2992) 
O
NO
N
R3
R4
R2
R1
 
Compound RR1 RR2 RR3 RR4 FP KRiR (µM)[a] ELISA ICR50R 
(µM)[a] 
30 (IPR-3011) 
N
O
N
O
NN
 
 
Me H 2.5 ± 0.3 15.5 ± 1.4 
31 (IPR-3015) 
O
O
NN
 
N  
Me H 37.1 ± 1.9 171.5 ± 35.7 
32 (IPR-3026) 
N O
  
Me Cl 15.4 ± 3.4 No inhibition 
33 (IPR-3036) 
N N
 
N  
Me H 5.2 ± 0.5 62.7 ± 10.7 
34 (IPR-3037) 
NN
 
N
 
Me H 8.0 ± 1.1 99.5 ± 14.2 
35 (IPR-3038) 
N
 
N  
Me H 11.9 ± 2.0 67.9 ± 11.2 
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36 (IPR-3039) 
N
 N  
Me H 8.4 ± 0.6 37.9 ± 2.4 
37 (IPR-3040) 
N
 
N  
Me H 26.6 ± 7.8 112.2 ± 8.6 
38 (IPR-3103) 
N
O
N
O
NN
 
 
Me H 5.2 ± 1.1 31.0 ± 2.1 
39 (IPR-3116) 
N N F
 N  
H H 10.4 ± 3.1 No inhibition 
40 (IPR-3117) 
N N
O
 
N  
H H 9.2 ± 1.9 331.6 ± 197.0 
41 (IPR-3121) Cl
NN
 
N  
H H 3.4 ± 0.5 34.4 ± 7.4 
42 (IPR-3134) 
NN
 
N  
Me H 9.9 ± 1.4 122.8 ± 15.3 
43 (IPR-3147) 
N N
O
 
N  
Cl H 2.5 ± 0.3 26.3 ± 6.8 
 
[a] Representative of at least two independent experiments, where each concentration point is 
measured in duplicates (mean ± SD). 
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FIGURE LEGENDS 
Figure 1. Workflow for the fingerprint method used to identify compounds that mimic the 
intermolecular binding interactions in the uPAR•uPA complex. The per-residue 
interaction energies of docked compounds are compared to those of the native 
protein ligand uPA. These interaction energies are used to generate a bitwise 
fingerprint, where each position on the fingerprint corresponds to the interaction 
energy between uPAR and the compound of interest. This fingerprint is compared 
to fingerprints of the native ligand uPA. Compounds are rank-ordered based on 
their Tanimoto distance with the fingerprints of uPA and total interaction energy 
∆ERGBTOTR. 
Figure 2. A virtual screen utilizing the interface residues of uPAR and validation of hits. a) 
Residues used in the uPAR fingerprints are colored on the surface of uPAR as 
follows: (i) Experimental alanine scan (orange), (ii) decomposition (pink), (iii) both 
(green). uPA is transparently overlaid in cartoon, with the side chain of interface 
residues in stick. b) Among the top-ranking 500 compounds from each of the 
fingerprints generated from decomposition energies or experimental alanine 
scanning, the proportion of compounds that overlap with each fingerprint residue.  
c) Single-concentration FP screen of compounds resulting from the virtual screen 
based on uPAR residues. Each compound was screened in duplicate at 50 µM 
concentration (mean ± SD). Hit compound 1 (IPR-2797) is highlighted in green. d)  
Concentration-dependent FP assay measuring the inhibition of uPAR•AE147-FAM 
peptide interaction by 1 (IPR-2797). Representative of at least two independent 
experiments, where each concentration point is measured in duplicates (mean ± 
SD). 
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Figure 3. Screening the derivatives of compound 1 (IPR-2797). a) The binding mode of 1 in 
the uPAR•uPA binding pocket. The compound is shown in yellow. uPAR is shown 
in white cartoon, with the side chain of interface residues shown in pink stick. uPA 
is shown in partial transparent cyan cartoon. The side chain of four interface 
residues on uPA are shown in stick and colored cyan. b) Derivatives of 1 were 
screened at a single 50 µM concentration via the uPAR•AE147-FAM peptide FP 
assay in duplicates (mean ± SD). Further pursued hits are highlighted in green. c) 
Chemical structures of the pursued derivative hits.  
Figure 4. A virtual screen utilizing four interface residues of uPA and validation of hits. a) 
Features of the pharmacophore model used to identify compounds that overlap 
with and mimic the interface residues of uPA. uPAR is shown in the background 
colored in white and shown in cartoon. uPA is shown in transparent cyan cartoon, 
with the five interface residues shown in stick. A pharmacophore model was used 
to assign features to four of the five interface residues (Ile-28 was excluded). The 
amine on the side chain of Lys-23 was assigned a positive ionizable feature 
(transparent red circle), while the aromatic rings of Tyr-24, Phe-25, and Trp-30 
were assigned aromatic ring features (transparent yellow circles). Two separate 
pharmacophore features were assigned to each of the two rings on the indole on 
Trp-30. b) Single-concentration FP screen of compounds resulting from the virtual 
screen based on uPA interface residues. Each compound was screened in 
duplicate at 50 µM concentration (mean ± SD). Hits that are followed up are 
highlighted in green while those with problematic moieties are highlighted in red. 
Chemical structures of the highlighted molecules are shown above. c) Co-
occurrence of interface residues among all compounds that overlapped with at 
least one residues on uPA. d) Overlap between the predicted binding mode of the 
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hit molecules and the uPA residues are highlighted. FP and microtiter ELISA 
assays were used to measure the KRiR and ICR50R of the compounds in inhibiting 
uPAR•AE147-FAM peptide and uPAR•uPARATF Rinteractions, respectively. Results 
are based on at least two independent concentration-dependent experiments 
where each concentration point was measured in duplicates (mean ± SD). 
Figure 5. Screening the derivatives of compounds 8 (IPR-2529) and 9 (IPR-2532). a) The 
virtual screening binding mode of 8 in the uPAR•uPA binding pocket. The 
compound is shown in yellow. uPAR is shown in white cartoon, with the side chain 
of interface residues shown in pink stick. uPA is shown in partial transparent cyan 
cartoon. The side chain of four interface residues on uPA are shown in stick and 
colored cyan. b) Derivatives of 8 were screened at a single 50 µM concentration 
via FP assay in duplicates (mean ± SD). Further pursued hits are highlighted in 
green. c) Chemical structures of the pursued derivative hits of 8. d) The virtual 
screening binding mode of 9 (IPR-2532) in the uPAR•uPA binding pocket. The 
compound is shown in yellow. uPAR is shown in white cartoon, with the side chain 
of interface residues shown in pink stick. uPA is shown in partial transparent cyan 
cartoon. The side chain of four interface residues on uPA are shown in stick and 
colored cyan. e) Derivatives of 9 were screened at a single 50 µM concentration 
via FP assay in duplicates (mean ± SD). Further pursued hits are highlighted in 
green. f) Chemical structures of the pursued derivative hits of 9.  
Figure 6. A virtual screen utilizing interface residues on both uPAR and uPA. a) Single-
concentration FP screen of compounds resulting from the virtual screen based on 
uPA interface residues. Each compound was screened in duplicate at 50 µM 
concentration (mean ± SD). Hits that are pursued are highlighted in green while 
those with problematic moieties are highlighted in red. Chemical structures of the 
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highlighted molecules are shown above. b) Overlap between the predicted binding 
mode of the hit molecules and the uPA interface residues are highlighted. FP and 
microtiter ELISA assays were used to measure the KRiR and ICR50R of the compounds 
in inhibiting uPAR•AE147-FAM peptide and uPAR•uPARATF Rinteractions, 
respectively. Results are based on at least two independent concentration-
dependent experiments where each concentration point was measured in 
duplicates (mean ± SD). 
Figure 7. Testing the derivatives of 26 (IPR-2992) leads to 30 (IPR-3011). a) The binding 
mode of 26 (IPR-2992) and 30 (IPR-3011) in the uPAR•uPA binding pocket. The 
binding mode of 30 (green) is overlaid on the binding mode of 26 (yellow). The 
additional ring at RR1R allows 30 to bind deeper in the uPAR•uPA pocket. uPAR is 
shown in white cartoon, with the side chain of interface residues shown in pink 
stick. b) The core of 26 was used to identify analogs at 5 positions. Among the 
analogs discovered was 30 (IPR-3011). c) Derivatives of 26 were screened at a 
single 50 µM concentration via the uPAR•AE147-FAM peptide FP assay in 
duplicates (mean ± SD). The parent compound 26 is highlighted in orange, while 
compound 30 is highlighted in green. d) Concentration-dependent FP assay 
measuring the inhibition of uPAR•AE147-FAM peptide interaction by 26 and 30. 
Representative of at least two independent concentration-dependent experiments 
where each concentration point was measured in duplicates (mean ± SD). At high 
concentrations, 30 was insoluble and as such the data points were omitted from 
curve-fitting. e) Concentration-dependent ELISA assay measuring inhibition of 
uPAR•uPARATFR interaction by 26 and 30. Representative of at least two independent 
concentration-dependent experiments where each concentration point was 
measured in duplicates (mean ± SD). At high concentrations, 30 was insoluble and 
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as such the data points were omitted from curve-fitting. f) MST experiment was 
performed with 40 nM NT-495-labeled uPAR and varying concentrations of 26. A 
representative MST concentration-response curve of the interaction between 
uPAR and 26 are shown. Two independent experiments were performed in 
triplicates (mean ± SD). g) MST experiment was performed with 40 nM NT-495-
labeled uPAR and varying concentrations of 30. A representative MST 
concentration-response curve of the interaction between uPAR and 30 are shown. 
Two independent experiments were performed in triplicates (mean ± SD). At high 
concentrations, 30 is insoluble and the high concentration points, in light orange, 
are omitted from curve fitting. 
Figure 8. Screening the derivatives of compound 28 (IPR-3089) and 29 (IPR-3193). a) The 
virtual screening binding mode of 28 in the uPAR•uPA binding pocket. The 
compound is shown in yellow. uPAR is shown in white cartoon, with the side chain 
of interface residues shown in pink stick. uPA is shown in partial transparent cyan 
cartoon. The side chain of four interface residues on uPA are shown in stick and 
colored cyan. b) Derivatives of 28 were screened at a single 50 µM concentration 
via FP assay in duplicates (mean ± SD). Further pursued hits are highlighted in 
green. c) Chemical structures of the pursued derivative hits of 28. KRiR values are 
based on two independent concentration-dependent inhibition assays performed 
in duplicates (mean ± SD). d) The virtual screening binding mode of 29 in the 
uPAR•uPA binding pocket. The compound is shown in yellow. uPAR is shown in 
white cartoon, with the side chain of interface residues shown in pink stick. uPA is 
shown in partial transparent cyan cartoon. The side chain of four interface residues 
on uPA are shown in stick and colored cyan. e) Derivatives of 29 were screened 
at a single 50 µM concentration via FP assay in duplicates (mean ± SD). Further 
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pursued hits are highlighted in green. f) Chemical structures of the pursued 
derivative hits of 29. KRiR values are based on two independent concentration-
dependent inhibition assays performed in duplicates (mean ± SD). 
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Mimicking protein-protein interactions: We explore mimicry of the pairwise intermolecular 
interactions of the native protein ligand with residues of the protein receptor in the tight protein-
protein interaction between urokinase and its receptor. We use both fingerprint and 
pharmacophore approaches to compare the binding profiles of the native ligand and docked 
compounds. We identify several small molecules with novel chemotypes that inhibited the tight 
interaction with single-digit micromolar ICR50Rs. 
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